| abstract |
The present invention relates to a pharmaceutical composition containing wogonin as an active ingredient for preventing or treating asthma. The wogonin of the present invention exhibits superior effects in that the wogonin relieves the hypersensitivity of airways which may cause asthma in vivo; restricts the amount of active oxygen produced in the airways; and inhibits the infiltration of inflammatory cells into the bronchial tubes. Further, the wogonin inhibits the generation of both egg albumin and, particularly, IgE, in a fluid for bronchoalveolar lavage and in a serum; and inhibits the expression of Th2 cytokine in the lungs. Thus, the wogonin may be valuably used as a composition for the prevention, treatment, or alleviation of asthma. |